Ernexa Therapeutics Inc.
ERNAWNasdaq
$0.07
↓ -14.9%Jul 17 close · end-of-day
Price
1Y↓ -32.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$53,856.00
Enterprise Value
$53,856.00
P/E
0.0
P/S
—
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$11.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-166.0%
ROIC
-140.3%
Debt / Equity
—
Net Cash
—
Return 1Y
—
Company profile
Earnings
ERNAW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$6.95↓ -88.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $5.8M | — | $0.00 | $68,000.00 | $582,000.00 | — |
| Gross profit | — | — | $0.00 | -$168,000.00 | $486,000.00 | — |
| Operating income | -$7.2M | -$113.7M | -$33.2M | -$21.1M | -$15.7M | -$9.3M |
| Net income | -$7.3M | -$122.5M | -$24.6M | -$21.7M | -$44.5M | -$14.1M |
| Diluted EPS | -$0.41 | -$56.61 | -$8.06 | -$4.08 | -$48.96 | -$2.24 |
| Operating cash flow | -$8.1M | -$23.5M | -$21.0M | -$20.4M | -$15.8M | -$7.0M |
| Free cash flow | -$8.1M | -$23.6M | -$21.3M | -$20.4M | -$16.2M | -$7.1M |
| Gross margin | — | — | — | -247.1% | 83.5% | — |
| Operating margin | -125.0% | — | — | -31080.9% | -2693.1% | — |
| Net margin | -125.7% | — | — | -31864.7% | -7652.7% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47,000.00 | $487,000.00 | $1,000.00 | — | — | — | — | — |
| Gross profit | -$48,000.00 | $547,000.00 | $1,000.00 | — | — | — | — | — |
| Operating income | -$4.9M | -$2.3M | -$2.7M | -$2.7M | -$2.5M | -$2.0M | -$2.1M | -$5.6M |
| Net income | -$5.5M | -$26.6M | -$5.8M | -$8.2M | -$3.1M | -$1.2M | -$1.5M | -$5.5M |
| Diluted EPS | -$15.34 | -$73.70 | $41.31 | -$57.76 | -$0.61 | -$0.15 | $56.28 | -$6.95 |
| Operating cash flow | -$2.3M | -$6.3M | -$3.5M | -$2.1M | -$2.5M | -$1.3M | -$1.1M | -$2.3M |
| Free cash flow | -$2.5M | -$6.3M | -$3.5M | — | — | — | — | -$2.3M |
| Gross margin | -102.1% | 112.3% | 100.0% | — | — | — | — | — |
| Operating margin | -10491.5% | -463.9% | -269700.0% | — | — | — | — | — |
| Net margin | -11763.8% | -5462.8% | -575900.0% | — | — | — | — | — |
Company news
Coming soonHeadlines for ERNAW will appear here once the news feed is connected.
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-02-10 | Cherington Charles | Buy | 4,000,000 | $0.50 | $2.0M | filing |
| 2025-06-21 | Gurrola Sandra M· Sr. VP of Finance | Option exercise | 30 | — | — | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.